Emerging therapies in castrate-resistant prostate cancer.
Curr Urol Rep
; 11(3): 152-8, 2010 May.
Article
en En
| MEDLINE
| ID: mdl-20425621
ABSTRACT
Prostate cancer is the most common cancer in men in the United States, and despite screening and early treatment, more than 27,000 men are predicted to die of the disease this year, almost all of whom will die of castrate-resistant, metastatic cancers that have progressed despite androgen deprivation therapy, also known as hormonal therapy. In recent years, an increased understanding of molecular mechanisms of prostate cancer progression and castration resistance has led to improved treatment strategies. This review focuses on emerging therapies for the treatment of castrate-resistant prostate cancer, with an emphasis on the importance of the drug targets as well as the state of current clinical trials, including those utilizing hormonal therapies, biological agents, and immunotherapy that are underway or have recently been completed.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Orquiectomía
/
Vacunas contra el Cáncer
/
Inhibidores de Histona Desacetilasas
/
Antagonistas de Andrógenos
/
Andrógenos
Tipo de estudio:
Prevalence_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
/
Male
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Curr Urol Rep
Asunto de la revista:
UROLOGIA
Año:
2010
Tipo del documento:
Article
País de afiliación:
Estados Unidos